Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · IEX Real-Time Price · USD
201.07
+7.74 (4.00%)
Apr 29, 2024, 4:00 PM EDT - Market closed
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees on December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
n/a
Profits / Employee
-$993,697
Market Cap
4.22B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 376 | 284 | 308.70% |
Dec 31, 2022 | 92 | 21 | 29.58% |
Dec 31, 2021 | 71 | 29 | 69.05% |
Dec 31, 2020 | 42 | 13 | 44.83% |
Dec 31, 2019 | 29 | 12 | 70.59% |
Dec 31, 2018 | 17 | 9 | 112.50% |
Dec 31, 2017 | 8 | 0 | - |
Dec 31, 2016 | 8 | -2 | -20.00% |
Dec 31, 2015 | 10 | -100 | -90.91% |
Dec 31, 2014 | 110 | -24 | -17.91% |
Dec 31, 2013 | 134 | 10 | 8.06% |
Dec 31, 2012 | 124 | 2 | 1.64% |
Dec 31, 2011 | 122 | 10 | 8.93% |
Dec 31, 2010 | 112 | -15 | -11.81% |
Dec 31, 2009 | 127 | -2 | -1.55% |
Dec 31, 2008 | 129 | -46 | -26.29% |
Dec 31, 2007 | 175 | 29 | 19.86% |
Dec 31, 2006 | 146 | 28 | 23.73% |
Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Merit Medical Systems | 6,950 |
Alkermes | 2,100 |
Alvotech | 1,026 |
Insmed | 912 |
Immunovant | 164 |
Alpine Immune Sciences | 142 |
MDGL News
- 5 days ago - Madrigal Statement on the Passing of Dr. Stephen Harrison - GlobeNewsWire
- 13 days ago - Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering - GlobeNewsWire
- 6 weeks ago - Madrigal Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 6 weeks ago - Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH - Reuters
- 6 weeks ago - FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease - CNBC
- 6 weeks ago - Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH - Market Watch
- 6 weeks ago - Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis - GlobeNewsWire